Executive Summary: The Specialty Drug Pipeline Will Break Small Group Stop Loss Pricing Within Five Years
TOS.11 — The Other Side#
The specialty drug pipeline of 2024 through 2030 is structurally different from prior drug cost shocks in ways that disrupt the repricing logic. The pipeline is not producing one or two drugs at extraordinary cost; it is producing dozens of therapies simultaneously, each capable of generating claims that exceed the annual specific stop loss attachment points of small group plans, targeting an expanding range of conditions. The actuarial assumption that carriers can price against this risk requires a predictable distribution of who will need these therapies and when. That distribution, across groups of 5 to 25 employees, is not calculable. Carriers will not absorb the cost. They will exit the smallest market segments, or reprice to levels that render level funded economically nonviable for groups under 15 lives. The timeline is five years, measured from when the approvals of 2023 through 2025 translate into covered claims for small group plans.
Prior drug cost shocks were concentrated. Sovaldi arrived in 2013 at $84,000 for a hepatitis C treatment course and cured a defined patient population with an estimable prevalence. Carriers modeled the exposure, increased premiums, and waited for the prevalence to decline. The cell and gene therapy pipeline operates differently. The FDA approved seven novel cell and gene therapies in 2023, setting a record; seven more followed in 2024. The Alliance for Regenerative Medicine projected 10 to 20 approvals annually by 2025 and beyond. The price points illustrate the scale: Hemgenix, approved for hemophilia B in 2022, was priced at $3.5 million per treatment. Casgevy and Lyfgenia, both approved for sickle cell disease in December 2023, were priced at $2.2 million and $3.1 million respectively. Lenmeldy, approved for metachromatic leukodystrophy in 2024, entered the market at $4.25 million.
The repricing has already started and is not keeping up. The Aegis Risk Medical Stop-Loss Premium Survey documents stop loss premiums increasing 16 percent from 2021 to 2023, with annualized increases from 2022 through 2024 ranging from 10.4 percent at a $100,000 deductible to 13.8 percent at a $750,000 deductible. The Aegis 2025 survey notes that 49 percent of respondents reported a claimant exceeding $1 million in paid claims in the last two policy years, and identifies three million dollar claims as “the new $1 million claim.” For a small group plan with 10 to 15 members, the question is not what percentage of the population will generate a catastrophic claim, but whether any single member will. The carrier loads the premium with enough uncertainty margin to compensate for that binary exposure, which makes the premium unaffordable, or accepts a margin too thin for the tail risk, which makes the carrier exit the segment. Interest in specialty prescription drug and gene therapy carve-out policies was reported by 21 percent of Aegis survey respondents in 2025, signaling that the main stop loss market is already treating the specialty drug pipeline as a risk category to isolate rather than absorb within standard pricing. The five-year timeline identifies when these signals become prevalent enough that the industry stops describing what is happening as a pricing cycle and starts naming it as a structural problem.